LM Kuitert, RM Angus, NC Barnes, PJ Barnes, MF Bone, KF Chung, AJ Fairfax, TW Higenbotham, BJ O'Connor and B Piotrowska
Department of Thoracic Medicine, London Chest Hospital and National Heart and Lung Institute, United Kingdom.

Platelet-activating factor (PAF), proposed as an important inflammatory mediator in asthma, reproduces several of the features of asthma, such as microvascular leakage, mucus secretion, bronchoconstriction, and possibly increased airway responsiveness. Modipafant (UK-80,067) is the (+)-enantiomer of UK-74,505, a potent and specific PAF antagonist. We have assessed the effect of modipafant over 28 d in adult subjects with moderately severe asthma in a placebo-controlled parallel group study. A total of 218 patients with asthma were enrolled into the single-blind run-in, of whom 120 (93 males and 27 females, mean age 41.0 yr) entered the double-blind treatment phase after demonstrating symptomatic asthma in the final week of the single-blind run-in phase. Patients could take up to 1600 micrograms inhaled corticosteroid and an inhaled beta 2 agonist as rescue medication. A total of 59 patients with asthma took modipafant (one 50 mg capsule twice daily), and 61 took matched placebo. There was no significant difference between placebo and modipafant in diurnal variation in PEF, morning and evening PEF, clinic FEV1, rescue bronchodilator usage, symptom score, or airway responsiveness. We previously showed that the racemate UK-74,505 had no effect on antigen challenge, and this study shows that the active (+)- enantiomer modipafant has no effect in chronic asthma. This suggests that PAF is not an important mediator in asthma.

This article has been cited by other articles:

				D. G. Souza, C. T. Fagundes, L. P. Sousa, F. A. Amaral, R. S. Souza, A. L. Souza, E. G. Kroon, D. Sachs, F. Q. Cunha, E. Bukin, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection PNAS, August 18, 2009; 106(33): 14138 - 14143. [Abstract] [Full Text] [PDF]

				N. R. HENIG, M. L. AITKEN, M. C. LIU, A. S. YU, and W. R. HENDERSON Jr. Effect of Recombinant Human Platelet-activating Factor-Acetylhydrolase on Allergen-induced Asthmatic Responses Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 523 - 527. [Abstract] [Full Text] [PDF]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				J. Tamaoki, I. Yamawaki, E. Tagaya, M. Kondo, K. Aoshiba, J. Nakata, and A. Nagai Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L351 - L357. [Abstract] [Full Text] [PDF]

				P. J. Barnes, K. F. Chung, and C. P. Page Inflammatory Mediators of Asthma: An Update Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596. [Abstract] [Full Text] [PDF]

				D. J. EVANS, P. J. BARNES, M. CLUZEL, and B. J. O'CONNOR Effects of a Potent Platelet-activating Factor Antagonist, SR27417A, on Allergen-induced Asthmatic Responses Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 11 - 16. [Abstract] [Full Text]